Stony Brook University

Artelo Biosciences' ART26.12 Advances in Phase 1 Trial for Neuropathic Pain

4 months ago

• Artelo Biosciences' ART26.12, a non-opioid drug, has successfully completed the safety review of its first cohort in a Phase 1 clinical trial. • The Safety Review Committee recommended advancing to the next dose level, marking a significant step in developing a novel treatment for neuropathic pain. • ART26.12, a selective FABP5 inhibitor, is being developed for chemotherapy-induced peripheral neuropathy, a condition affecting millions. • The Phase 1 trial's next phase will involve more subjects and assess higher doses, with initial data expected in the first half of 2025.

Jennifer Jao Appointed Co-Chair of IMPAACT Network to Advance Pediatric HIV Clinical Trials

4 months ago

• Dr. Jennifer Jao of Northwestern University will co-chair the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network. • IMPAACT, funded by the NIH, is the largest global HIV clinical-trials network focused on pregnant, pediatric, and adolescent populations. • Dr. Jao will help shape the scientific agenda and lead operations to improve the health of individuals affected by HIV worldwide. • Jao's prior work includes IMPAACT P1115, showing remission in children with HIV after early treatment and antiretroviral therapy pause.

Trump Administration Reshapes Health Agencies; FDA Approves Novel Cancer Therapies

7 months ago

• President-elect Trump nominates Robert F. Kennedy Jr. as HHS Secretary, Mehmet Oz to lead CMS, and Marty Makary to head the FDA, signaling a shift in healthcare priorities. • The FDA grants accelerated approval to asciminib for chronic myeloid leukemia and obecabtagene autoleucel for B-cell acute lymphoblastic leukemia, marking advancements in cancer treatment. • Revumenib receives approval for relapsed or refractory acute leukemia with KMT2A translocation, offering a targeted therapy for this specific genetic alteration. • A new Surgeon General's report highlights disparities in tobacco use, emphasizing the need for tailored interventions in vulnerable populations.